Respiri signs key deal with UK research centre as it prepares for European launch
Health & Biotech
Health & Biotech
Link copied to
Special Report: The agreement will see data from Respiri’s propriety wheezo technology collated to improve outcomes for asthma research.
For electronic health company Respiri (ASX:RSH), the focus is now on expanding the global distribution strategy for its flagship wheezo® product – a tech platform that uses machine learning to detect wheezing and other symptoms of asthma.
And this morning, the company announced a new partnership with a research centre at the University of Edinburgh in Scotland, dedicated to finding improved solutions for respiratory health conditions.
Led by epidemiologist Aziz Sheikh and equipped with a substantial research budget, the university’s Data Research Hub for Respiratory Health focuses on how health outcomes can be improved using technology and data analytics.
The respiratory health centre is one of seven new research hubs, funded by a four-year, £37m (~$67m) investment backed by the UK government.
Commenting on the deal, CEO Marjan Mikel said the announcement came at an important time for Respiri, given it had already received CE Mark approval from European health regulators.
“The wheezo® technology brings cutting edge innovation for the monitoring of respiratory disease, and this is an opportunity to demonstrate how the platform is beneficial to patients, the industry and the NHS,” Mikel said.
With a university-led pathway to demonstrate the use-case for its product, Respiri now has the ideal platform to launch wheezo into the European market in 2021.
“Our partner, Professor Sheikh and his team at the hub intend to be at the forefront of digitally-enabled respiratory health, and we are honoured to be a part of it,” Mikel said.
Prior to its European launch, Respiri remains on track to complete the commercial rollout of wheezo into the Australian market in the December quarter.